Skip to main content
Fig. 4 | Biomaterials Research

Fig. 4

From: Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway

Fig. 4

In vitro cellular mode for checking the ZnPcS passage across the BBB (n = 3). a HUVEC are cultured on a transwell membrane insert, and U87-glioma cells are cultured on the bottom of the well. Twenty-four hours after TMZ treatment, the U87-glioma cells are stained with DAPI and imaged. b HUVEC are cultured on a transwell membrane insert, and U87-glioma cells are cultured on the bottom of the well. Twenty-four hours after 5 µM ZnPcS treatment, U87-glioma cells are stained with DAPI and imaged. c HUVEC are cultured on the transwell membrane insert, and U87-glioma cells are cultured on the bottom of the well. Twenty-four hours after 10 µM ZnPcS treatment, U87-glioma cells are stained with DAPI and imaged. d HUVEC are cultured on a transwell membrane insert, and fibroblasts are cultured on the bottom of the well. Twenty-four hours after 5 µM ZnPc treatment, U87-glioma cells are stained with DAPI and imaged. In all the images, the blue fluorescent represents the nucleus, and the red fluorescent represents the ZnPcS. All the schematics show the sequence of cells in the transwells. ZnPcS (red fluorescence) is excited at 633 nm and monitored at 710 nm, and nucleus (blue fluorescence) is excited at 405 nm and monitored at 459 nm. Scale bar = 100 μm

Back to article page